Bernard C. Rudnick

Bernard C. Rudnick is founder and managing partner of CapGenic Advisors, LLC, and a member/founder of several investment groups. He is CFO and Director of Atrin Pharmaceuticals and was Director and CFO of Immunomic Therapeutics, two FiReStarter companies. Immunomic Therapeutics completed a license with Astellas which resulted in the largest ($300M) upfront payment in its class of drugs and a $130M distribution to investors.

Mr. Rudnick’s entrepreneurial career spans a number of startups, three of which grew to over $50M in revenue before liquidity events. With 38 years experience in executive-level strategy, finance, and management, Mr. Rudnick has senior merger, acquisition, capital formation, and licensing leadership experience for start-ups to Fortune 50 companies. He has substantial experience investing and guiding entrepreneurial companies, and has led capital formation of $538M and strategic and licensing transactions of $7B. His advisory clients have included Mitsui (Mitrix), DuPont (Agri-chemical), McKesson Bioservices (now TMO),and Kika Clinical Solutions (now IBM).